Login to Your Account



Early Data: Sangamo's SB-509 Improves ALS Muscle Function

By Jennifer Boggs


Thursday, December 10, 2009
Sangamo BioSciences Inc. reported promising early data from its Phase II trial of zinc finger protein therapeutic SB-509, showing that it improved muscle function in amyotrophic lateral sclerosis patients, though it remains to be seen whether those results will translate into a win for the company down the road. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription